On Friday, Marathon Petroleum Corp(NYSE:MPC)’s shares inclined 0.02% to $46.35.
On Wednesday, Sept. 9, Marathon Petroleum Corporation (MPC) President and CEO Gary R. Heminger will deliver a presentation to investors and industry analysts at the Barclays CEO Energy-Power Conference in New York City.
Heminger`s presentation is planned to start at 8:25 a.m. EDT. The live webcast and archived presentation can be viewed on Marathon Petroleum`s Investor Relations website, http://ir.marathonpetroleum.com. The archived webcast and presentation support materials will be accessible for 14 days following Heminger`s presentation.
Marathon Petroleum Corporation, together with its auxiliaries, engages in refining, marketing, retailing, and transporting petroleum products primarily in the United States. It operates through three segments: Refining & Marketing, Speedway, and Pipeline Transportation. The company refines crude oil and other feed stocks at its seven refineries in the Gulf Coast and Midwest regions of the United States; and purchases ethanol and refined products for resale.
Tyson Foods, Inc. (NYSE:TSN)’s shares gained 0.02% to $42.14.
After donating 100 million pounds of food over the past 15 years, Tyson Foods, Inc. (TSN) is making a new commitment to hunger relief. The company declared recently it is pledging $50 million in cash and in-kind donations over the next five years in the fight against hunger, with a special focus on innovative initiatives at the local level.
This commitment builds on Tyson’s long partnership with hunger relief organizations, counting Share Our Strength, Feeding America, and the Food Research and Action Center.
As part of its five-year commitment, Tyson will recognize individuals on the frontlines of fighting hunger in their communities, like Lola Stephens-Bell of Austin, Texas. In a recent documentary-style film, Tyson follows Lola through her weekly routine: running her restaurant where she also serves free meals out the back door, and closing the restaurant four days a week to drive meals to underserved people in Austin.
Tyson Foods, Inc., together with its auxiliaries, produces, distributes, and markets chicken, beef, pork, prepared foods, and related allied products worldwide. The company breeds and raises chickens; and processes live chickens into fresh, frozen, and value-added chicken products. It also processes live fed cattle, and live market hogs and allied products; fabricates pork and dressed beef carcasses into primal and sub-primal cuts and case-ready products; and sells hides and meats.
At the end of Friday’s trade, Discovery Communications Inc. (NASDAQ:DISCA)‘s shares dipped -1.44% to $26.73.
Discovery Communications ( DISCA) will report third quarter 2015 results on Tuesday, November 3, 2015, at 7:00 a.m. ET. The company will host a conference call at 8:30 a.m. ET to talk about the results.
Discovery Communications, Inc. operates as a media company. The company operates through U.S. Netoperates; International Netoperates; and Education and Other segments. The company owns and operates television netoperates under the brands, such as Discovery, TLC, Animal Planet, Investigation Discovery, Science, Velocity, Discovery Family, American Heroes, Destination America, Discovery Life, Oprah Winfrey network, Eurosport, DMAX, and Discovery Kids. Its content spans genres, counting survival, exploration, sports, lifestyle, general entertainment, heroes, adventure, crime and investigation, health, and kids. \
Array Biopharma Inc (NASDAQ:ARRY), ended its Friday’s trading session with -2.6% loss, and closed at $5.62.
Array BioPharma (ARRY) declared that it has designated Patricia Henahan to the position of Chief Financial Officer. Ms. Henahan has extensive financial experience in the biopharmaceutical industry counting leadership roles at Hospira, AstraZeneca, Eli Lilly and MedImmune. She has strong expertise in planned planning, financial analysis, commercialization, R&D, operations and alliance administration. Preceding to joining Array, Ms. Henahan was Vice President of Finance for Hospira’s $3 billion U.S. pharmaceutical-focused business. During her tenure, Hospira delivered double-digit profit growth and achieved its highest ever U.S. market share and revenue level. She joins Array in advance of several noteworthymilestones, counting top-line results from the NEMO and COLUMBUS Phase 3 pivotal trials and projected regulatory filings of wholly-owned binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor.
Preceding to her role at Hospira, Ms. Henahan was Chief Financial Officer of iPR Pharmaceuticals, Inc., AstraZeneca Group, from 2009 to 2013, where she was responsible for revenue of $5 billion. From 2002 to 2009, Ms. Henahan offered financial leadership to the R&D organizations of AstraZeneca, MedImmune and Eli Lilly. In these roles, she worked closely with R&D executives to manage R&D operations, partnershipagreements, and budgets in excess of $600 million. Ms. Henahan holds an MBA from The Wharton School at the University of Pennsylvania and a bachelor’s degree in science from the University of Notre Dame.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companys drugs in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASC08/Danoprevir, a protease inhibitor for Hepatitis C virus; ASLAN001/ARRY-543, a pan-HER inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; and LY2606368, a chk-1 inhibitor for cancer.
\DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
